Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
Top Page
BioLife Solutions
(NASDAQ:BLFS)
Rating:55Neutral
Price Target:
$22.50
▲(8.28%Upside)
Positive Factors
Acquisitions
The acquisition of PanTHERA CryoSolutions is expected to enhance BioLife's capabilities in cryopreservation solutions.
Financial Performance
BioLife Solutions reported strong financial performance in 4Q24, with total revenue exceeding projections and a net loss lower than expected.
Market Position
BioLife completed the acquisition of PanTHERA CryoSolutions, which strengthens BioLife’s market leading position in biopreservation.
Negative Factors
Market Risks
Risks include lower-than-projected growth, inability to secure additional customers, sales fluctuations in emerging markets, and potential dilution risk.
Revenue Projections
Total revenue was $23.9M, representing a 24.5% YoY decline and missing the projection of $26.0M.
BioLife Solutions (BLFS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05B
Dividend YieldN/A
Average Volume (3M)566.36K
Price to Earnings (P/E)―
Beta (1Y)1.99
Revenue Growth-23.12%
EPS Growth97.46%
CountryUS
Employees159
SectorHealthcare
Sector Strength40
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.01
Shares Outstanding47,835,213
10 Day Avg. Volume389,116
30 Day Avg. Volume566,356
Financial Highlights & Ratios
PEG Ratio-1.98
Price to Book (P/B)2.79
Price to Sales (P/S)0.00
P/FCF Ratio88.58
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit15.70
Enterprise Value/Ebitda-13.64
Forecast
1Y Price Target
$31.33Price Target Upside50.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
BioLife Solutions Business Overview & Revenue Model
Company DescriptionBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
How the Company Makes MoneyBioLife Solutions generates revenue primarily through the sale of its proprietary biopreservation media and automated thawing devices. The company's revenue streams include direct sales to biotechnology and pharmaceutical companies, as well as academic and government research institutions. Additionally, BioLife may engage in strategic partnerships and collaborations with other industry players to expand its market reach and enhance its product offerings. The company's earnings are significantly influenced by the growing demand for advanced cell therapies and regenerative medicine, as its products play a crucial role in maintaining cell integrity throughout the supply chain.
BioLife Solutions Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: -7.07%|
Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment Positive
The earnings call reflected a strong start to 2025 with significant revenue growth and improved profitability. A strategic acquisition and a robust financial position further highlight BioLife's positive trajectory. Potential challenges from industry headwinds were acknowledged, but their impact is not expected to be material in the near term.Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Total revenue increased by 30% year-over-year, with cell processing revenue up 33%. This marks the sixth consecutive quarter of revenue growth.
Enhanced EBITDA Margin
Adjusted EBITDA margin expanded to 24%, up from 14% in the prior year, demonstrating strong operational efficiency.
Acquisition of PanTHERA CryoSolutions
The acquisition expands BioLife's biopreservation portfolio and enhances scientific capabilities, reinforcing its leadership in bioproduction consumables.
Strong Financial Position
BioLife ended the quarter with over $100 million in cash, providing a solid foundation for future growth.
Reaffirmed Financial Guidance
BioLife reaffirmed its full-year revenue guidance of $95.5 million to $99 million, with expected growth led by the cell processing platform.
Negative Updates
Operating Expenses Increase
GAAP operating expenses for Q1 2025 were $25.2 million, up from $21.7 million in Q1 2024, due to increased cost of sales and acquisition-related fees.
Potential Industry Headwinds
Near-term uncertainty from tariffs, NIH funding cuts, and FDA leadership changes could create headwinds across the ecosystem, though no material impact is expected currently.
Company Guidance
In the first quarter of 2025, BioLife Solutions delivered a strong financial performance, with cell processing revenue increasing by 33% year-over-year to $21.6 million, contributing to a total revenue of $23.9 million, up 30% from the previous year. The company also reported an adjusted EBITDA margin of 24%. BioLife's core biopreservation media (BPM) product line remains a key driver, with 60% of BPM revenue coming from direct sales and 40% from distribution. Notably, 40% of total BPM revenue is derived from customers with approved commercial therapies. At the end of Q1, BioLife's BPM products were used in 17 approved therapies, with an estimated 70% usage in U.S. commercially sponsored CGT trials. The company reaffirmed its full-year revenue guidance of $95.5 million to $99 million, forecasting 16% to 20% growth. Adjusted gross margin is expected to remain in the mid-60% range.BioLife Solutions Financial Statement Overview
Summary
BioLife Solutions is facing declining revenues and persistent losses impacting profitability. While the gross profit margin remains strong and the balance sheet is stable with a high equity ratio, the negative revenue growth and profitability are concerning. However, improvements in cash flow management are notable.Income Statement
BioLife Solutions has faced challenges in maintaining revenue growth, with a decline from $161.76M in 2022 to $79.42M in TTM (Trailing-Twelve-Months). The gross profit margin is strong at 76.5% in TTM, but the company is struggling with profitability as indicated by a negative net profit margin of -13.1% and negative EBIT and EBITDA margins. The revenue growth rate is negative, reflecting a downward trend in sales.45
Neutral
Balance Sheet
The company's balance sheet shows a solid equity base with a high equity ratio of 89.2% in TTM, indicating financial stability. However, the debt-to-equity ratio is low at 0.08, suggesting limited leverage. The return on equity is negative due to ongoing losses, which is a concern for investors.55
Neutral
Cash Flow
BioLife Solutions has improved its cash flow position, with a positive free cash flow of $11.29M in TTM, up from $5.20M in 2024. The operating cash flow to net income ratio is positive, indicating efficient cash generation relative to net income losses. The company has managed to grow its free cash flow significantly, which is a positive sign despite net losses.60
Neutral
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 82.25M | 143.27M | 161.76M | 119.16M | 48.09M |
| Gross Profit | 57.75M | 46.75M | 53.82M | 37.75M | 27.44M |
| EBITDA | 1.53M | -45.24M | -23.19M | -17.78M | 1.07M |
| Net Income | -20.18M | -66.43M | -139.81M | -8.38M | 2.67M |
Balance Sheet | |||||
| Total Assets | 399.49M | 412.71M | 450.23M | 552.60M | 234.83M |
| Cash, Cash Equivalents and Short-Term Investments | 104.58M | 51.70M | 64.06M | 69.87M | 90.46M |
| Total Debt | 30.17M | 42.69M | 43.71M | 26.88M | 11.15M |
| Total Liabilities | 50.58M | 75.05M | 86.04M | 71.85M | 29.58M |
| Stockholders Equity | 348.91M | 337.66M | -246.91M | 480.75M | 205.25M |
Cash Flow | |||||
| Free Cash Flow | 5.20M | -18.88M | -18.87M | -13.22M | 1.88M |
| Operating Cash Flow | 8.43M | -12.50M | -8.49M | -4.84M | 6.51M |
| Investing Cash Flow | 58.30M | 17.84M | -58.12M | -12.64M | -23.73M |
| Financing Cash Flow | -6.78M | 10.59M | 16.32M | -2.78M | 101.22M |
BioLife Solutions Technical Analysis
Negative
20.78
Price Trends
22.34
Negative
23.32
Negative
24.44
Negative
Market Momentum
-0.15
Positive
40.13
Neutral
27.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLFS, the sentiment is Negative. The current price of 20.78 is below the 20-day moving average (MA) of 21.86, below the 50-day MA of 22.34, and below the 200-day MA of 24.44, indicating a bearish trend. The MACD of -0.15 indicates Positive momentum. The RSI at 40.13 is Neutral, neither overbought nor oversold. The STOCH value of 27.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLFS.
BioLife Solutions Risk Analysis
BioLife Solutions disclosed 34 risk factors in its most recent earnings report. BioLife Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioLife Solutions Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $1.48B | ― | -2.00% | ― | -2.76% | 48.51% | |
55 Neutral | $1.05B | ― | -3.29% | ― | -23.12% | 97.46% | |
55 Neutral | $856.80M | 55.81 | -19.14% | ― | -14.44% | -557.38% | |
52 Neutral | $7.53B | 0.20 | -63.81% | 2.31% | 16.15% | 0.40% | |
44 Neutral | $1.08B | ― | -77.86% | ― | ― | -1.00% | |
| ― | $6.86B | 787.95 | 15.00% | ― | ― | ― | |
34 Underperform | $792.31M | ― | -130.38% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BLFS
BioLife Solutions
20.78
-1.73
-7.69%
AZTA
Azenta
31.91
-23.36
-42.27%
STAA
Staar Surgical
16.86
-27.37
-61.88%
PLSE
Pulse Biosciences
15.22
-1.16
-7.08%
NNNN
Anbio Biotechnology Class A
47.75
42.08
742.15%
KMTS
Kestra Medical Technologies Ltd.
16.29
-4.70
-22.39%
BioLife Solutions Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
BioLife Solutions Strengthens Board with Tony J. Hunt Appointment
Positive
Dec 20, 2024
BioLife Solutions has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors effective January 2, 2025. Mr. Hunt, recognized for his leadership in bioprocessing innovation, is expected to enhance BioLife’s strategic focus on the CGT market with his extensive industry experience, contributing to the company’s growth and innovation efforts. This appointment reflects BioLife’s commitment to strengthening its position in the bioprocessing sector and supporting its mission of delivering top-tier bioproduction workflows.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.